Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develop… Read more
Arcus Biosciences Inc (RCUS) - Total Assets
Latest total assets as of September 2025: $974.00 Million USD
Based on the latest financial reports, Arcus Biosciences Inc (RCUS) holds total assets worth $974.00 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Arcus Biosciences Inc - Total Assets Trend (2016–2024)
This chart illustrates how Arcus Biosciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Arcus Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Arcus Biosciences Inc's total assets of $974.00 Million consist of 88.4% current assets and 11.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.0% |
| Accounts Receivable | $25.00 Million | 2.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Arcus Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Arcus Biosciences Inc's current assets represent 88.4% of total assets in 2024, a decrease from 90.9% in 2016.
- Cash Position: Cash and equivalents constituted 13.0% of total assets in 2024, down from 59.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 2.2% of total assets.
Arcus Biosciences Inc Competitors by Total Assets
Key competitors of Arcus Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Arcus Biosciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Arcus Biosciences Inc generates 0.22x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Arcus Biosciences Inc is currently not profitable relative to its asset base.
Arcus Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.65 | 5.24 | 6.05 |
| Quick Ratio | 3.65 | 5.24 | 6.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $622.00 Million | $ 912.00 Million | $ 614.15 Million |
Arcus Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Arcus Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.37 |
| Latest Market Cap to Assets Ratio | 1.49 |
| Asset Growth Rate (YoY) | 5.0% |
| Total Assets | $1.15 Billion |
| Market Capitalization | $1.72 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Arcus Biosciences Inc's assets above their book value (1.49 x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Arcus Biosciences Inc's assets grew by 5.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Arcus Biosciences Inc (2016–2024)
The table below shows the annual total assets of Arcus Biosciences Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.15 Billion | +5.02% |
| 2023-12-31 | $1.09 Billion | -18.59% |
| 2022-12-31 | $1.34 Billion | -15.51% |
| 2021-12-31 | $1.59 Billion | +106.13% |
| 2020-12-31 | $772.29 Million | +280.23% |
| 2019-12-31 | $203.11 Million | -26.12% |
| 2018-12-31 | $274.93 Million | +44.33% |
| 2017-12-31 | $190.49 Million | +73.64% |
| 2016-12-31 | $109.70 Million | -- |